In connection with the war, several hundred thousand Israeli military reservists were called up to service. With the exception of one employee, all of our Israeli personnel (including employees, consultants and directors) are exempt from military reserve duty, including our Chief Executive Officer and Chief Financial Officer. The single employee who was called up has since returned to work. As of the date of this annual report, we have not experienced any impact to patient treatment visits in accordance wit ...

TEL AVIV, Israel, Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after th ...

TEL AVIV, Israel, Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will participate in two upcoming investor conferences. Dr. Mor will deliver a corporate presentation and participate  in one-on-one investor meetings at the Oppenhei ...

—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the Potential of Chemomab's CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC— —CM-101 Phase 2 PSC Trial Has Completed Patient Enrollment with Topline Data Readout Targeted for Midyear 2024—  TEL AVIV, Israel, Jan. 30, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clini ...

Chemomab Therapeutics Ltd. and its subsidiaries As of September 30, 2023 Chemomab Therapeutics Ltd. and its subsidiaries Condensed Consolidated Interim Balance Sheets F-3 Condensed Consolidated Interim Statements of Changes in Equity F-5 Notes to the Condensed Consolidated Interim Financial StatementsF-8 - F-11 Contents The accompanying notes are an integral part of the condensed consolidated interim financial statements (*) 1 American Depositary Share (ADS) represents 20 Ordinary Shares The accompanying no ...

Chemomab Therapeutics Ltd. and its subsidiaries Condensed Consolidated Interim Financial Statements Chemomab Therapeutics Ltd. and its subsidiaries Contents 5-6 Condensed Consolidated Balance Sheets The accompanying notes are an integral part of the condensed consolidated interim financial statements. | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------|--------------------------------------|--------------------------------------|-------------------- ...

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Adi Mor - Co-Founder and Chief Scientific Officer Matt Frankel - Chief Medical Officer, Vice President of Drug Development Don Marvin - Chief Financial Officer, Executive Vice President & Chief Operating Officer Conference Call Participants Kristen Kluska - Cantor Fitzge ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Kiryat Atidim, Building 7 Tel Aviv, Israel 6158002 (Address of principal executive offices including zip code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was requi ...

If Chemomab does not achieve its projected development and commercialization goals in the timeframes it announces and expects, the commercialization of its product candidates may be delayed and Chemomab's business will be harmed. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. A product candidate can fail at any stage of testing, even after observing promising signals of activity in earlier preclinical studies or clinical trials. The result ...

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Don Marvin - Chief Financial Officer, Executive Vice President and Chief Operating Officer Adi Mor - Co-Founder and Chief Scientific Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppe ...